Abeona Therapeutics Inc. (ABEO) stock
ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/3039% below fair value
$2.42+0.13 (+5.68%)
Close on Nov 13, 2026Market cap $138.39MP/E –Yield –
Abeona Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Abeona Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 65.1%. For fiscal 2025 it was 73.7%, against 100.0% the year before. The highest annual figure on record is 100.0% in fiscal 2014.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 73.7% | −26.3 |
| FY2014 | Dec 31, 2014 | 100.0% | +6.1 |
| FY2013 | Dec 31, 2013 | 93.9% | −0.1 |
| FY2012 | Dec 31, 2012 | 93.9% | +2.0 |
| FY2011 | Dec 31, 2011 | 92.0% | +21.1 |
| FY2010 | Dec 31, 2010 | 70.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 57.7% | – |
| Q2 FY2026 | Jun 30, 2026 | 63.3% | – |
| Q1 FY2026 | Mar 31, 2026 | 69.1% | – |
| Q4 FY2025 | Dec 31, 2025 | 80.7% | – |
See a number that looks wrong?